Evidence map›Paper›PMID 10482571›Full record

ArticleJournal of virology1999

Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

P S Polacino, V Stallard, J E Klaniecki, S Pennathur, D C Montefiori, A J Langlois, B A Richardson, W R Morton, R E Benveniste, S L Hu

Abstract read
In one paragraph

Article in Journal of virology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Non-human primate models for AIDS vaccine research.Current drug targets. Infectious disorders · 2005
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

P S PolacinoRegional Primate Research Center, University of Washington, Seattle, USA.
V Stallard
J E Klaniecki
S Pennathur
D C Montefiori
A J Langlois
B A Richardson
W R Morton
R E Benveniste
S L Hu

Funding

YILMA SIV VACCINIA VACCINE TRIALP51RR000166 · NCRR · UNIVERSITY OF WASHINGTON · PI CHAMBERLAIN, JEFFREY S · 1985 to 2011
$161.1M
PRIMATE IMMUNOLOGY LABORATORY FOR AIDS VACCINE R&DN01AI085343 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI LETVIN, NORMAN L · 1998 to 2000
$412k
NCRR NIH HHS P51 RR000166NCRR NIH HHS RR00166NIAID NIH HHS AI26503NIAID NIH HHS AI85343
6 · The paper itself

Abstract

We previously showed that envelope (gp160)-based vaccines, used in a live recombinant virus priming and subunit protein boosting regimen, protected macaques against intravenous and intrarectal challenges with the homologous simian immunodeficiency virus SIVmne clone E11S. However, the breadth of protection appears to be limited, since the vaccines were only partially effective against intravenous challenge by the uncloned SIVmne. To examine factors that could affect the breadth and the efficacy of this immunization approach, we studied (i) the effect of priming by recombinant vaccinia virus; (ii) the role of surface antigen gp130; and (iii) the role of core antigens (Gag and Pol) in eliciting protective immunity. Results indicate that (i) priming with recombinant vaccinia virus was more effective than subunit antigen in eliciting protective responses; (ii) while both gp130 and gp160 elicited similar levels of SIV-specific antibodies, gp130 was not as effective as gp160 in protection, indicating a possible role for the transmembrane protein in presenting functionally important epitopes; and (iii) although animals immunized with core antigens failed to generate any neutralizing antibody and were infected upon challenge, their virus load was 50- to 100-fold lower than that of the controls, suggesting the importance of cellular immunity or other core-specific immune responses in controlling acute infection. Complete protection against intravenous infection by the pathogenic uncloned SIVmne was achieved by immunization with both the envelope and the core antigens. These results indicate that immune responses to both antigens may contribute to protection and thus argue for the inclusion of multiple antigens in recombinant vaccine designs.

Indexed as

AnimalsAntigens, ViralGene Products, envImmunityImmunizationMacacaSAIDS VaccinesSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAntigens, ViralGene Products, envSAIDS Vaccinessimian immunodeficiency virus gp130SIV envelope glycoprotein gp160

Identifiers

PMID10482571
PMCPMC112838

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.